Market Overview

Recap: argenx Q3 Earnings


Shares of argenx (NASDAQ:ARGX) decreased 6.1% in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were down 450.00% year over year to ($3.96), which missed the estimate of ($2.81).

Revenue of $8,968,000 declined by 5.78% year over year, which missed the estimate of $16,850,000.


argenx hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: Oct 22, 2020

Time: 08:30 AM

ET Webcast URL:

Recent Stock Performance

52-week high: $284.00

52-week low: $103.75

Price action over last quarter: Up 4.79%

Company Profile

argenx SE is a clinical stage biotechnology company. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Its product pipeline includes product candidates such as ARGX-111, ARGX-109, ARGX-115, ARGX-112, and others. The company operates in the Netherlands, Germany, Denmark, Belgium, Switzerland, the United States, and Luxembourg. It derives the majority of its revenues from Switzerland.


Related Articles (ARGX)

View Comments and Join the Discussion!

Posted-In: Earnings News